Effects of Alagebrium, an Advanced Glycation End-Product Breaker, in Patients with Chronic Heart Failure: Study Design and Baseline Characteristics of the BENEFICIAL Trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims: Previous small open label studies have shown that the advanced glycation end-product (AGE) breaker alagebrium may improve cardiac function in patients with chronic heart failure (HF). We report the design, methods and baseline characteristics of a double-blind, placebo-controlled, randomized trial evaluating the efficacy and safety of alagebrium (BENEFICIAL) in patients with HF and a left ventricular ejection fraction (LVEF) ≤ 0.45. Methods and results: Patients with NYHA II–IV stable HF for at least 3 months were eligible for this study. One hundred and two patients were included in the study and randomized to either 200 mg alagebrium twice daily or placebo for a period of 36 weeks. The mean age of patients was 60 ± 11 years, 78% were male, and 17% were diabetic. Mean peak VO2 was 21.7 ± 5.9 mL/min/kg, mean LVEF was 0.32 ± 0.09. Diastolic function was worse (mean early tissue diastolic velocity (E′) 4.6 ± 1.7 vs. 6.1 ± 2.0 cm/s; P < 0.001) in patients with LVEF ≤ 0.35 compared to patients with LVEF between 0.35 and 0.45. Conclusion: The BENEFICIAL study is a proof-of-concept study that will provide new data on the efficacy and safety of the AGE crosslink breaker alagebrium in systolic HF patients. EudraCT number of this trial is NCT00516646.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography
Nagueh, S. F., Appleton, C. P., Gillebert, T. C., Marino, P. N., Oh, J. K., Smiseth, O. A., Waggoner, A. D., Flachskampf, F. A., Pellikka, P. A., & Evangelista, A. (2009) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.11.023 · Cited by 4,367
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Flynn, K. E., Piña, I. L., Whellan, D. J., Lin, L., Blumenthal, J. A., Ellis, S. J., Fine, L. J., Howlett, J. G., Keteyian, S. J., Kitzman, D. W., et al. (2009) · JAMA · doi:10.1001/jama.2009.457 · Cited by 737
Yoshida, N., Okumura, K.-I., & Aso, Y. (2005) · Metabolism · doi:10.1016/j.metabol.2004.09.014 · Cited by 138 · cited 1×
“Circulating AGEs have been correlated with vascular compliance in humans and may therefore also induce vascular stiffening.(19) Diastolic, systolic, and vascular dysfunction may cause decreased exercise capacity (Figure 1).”
Background
Cited by
Iron deficiency in chronic heart failure: an international pooled analysis
Klip, I. T., Comin-Colet, J., Voors, A. A., Ponikowski, P., Enjuanes, C., Banasiak, W., Lok, D. J., Rosentryt, P., Torrens, A., Polonski, L., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.01.017 · Cited by 736
Age-Related Intimal Stiffening Enhances Endothelial Permeability and Leukocyte Transmigration
Huynh, J., Nishimura, N., Rana, K., Peloquin, J. M., Califano, J. P., Montague, C. R., King, M. R., Schaffer, C. B., & Reinhart-King, C. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002761 · Cited by 402
Fishman, S. L., Sonmez, H., Basman, C., Singh, V., & Poretsky, L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0060-3 · Cited by 330
Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects
López, B., González, A., Hermida, N., Valencia, F., de Teresa, E., & Díez, J. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00335.2010 · Cited by 252
Signature of Circulating microRNAs in Patients with Acute Heart Failure
Ovchinnikova, E. S., Schmitter, D., Vegter, E. L., ter Maaten, J. M., Valente, M. A. E., Liu, L. C. Y., van der Harst, P., Pinto, Y. M., de Boer, R. A., Meyer, S., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.332 · Cited by 196
Self-citation
Metadata
- Authors
- Willemsen, S., Hartog, J. W. L., Hummel, Y. M., Posma, J. L., van Wijk, L. M., van Veldhuisen, D. J., & Voors, A. A.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02-15
- Volume
- 12
- Issue
- 3
- Pages
- 294-300
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W1982711845
- Cited by
- 53
- References
- 5
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Alagebrium, an Advanced Glycation End-Product Breaker, in Patients with Chronic Heart Failure: Study Design and Baseline Characteristics of the BENEFICIAL Trial. https://app.cochat.ai/papers/10.1093/eurjhf/hfp207
- The paper
- Willemsen, S., Hartog, J. W. L., Hummel, Y. M., Posma, J. L., van Wijk, L. M., van Veldhuisen, D. J., & Voors, A. A. (2010). Effects of Alagebrium, an Advanced Glycation End-Product Breaker, in Patients with Chronic Heart Failure: Study Design and Baseline Characteristics of the BENEFICIAL Trial. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfp207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.